Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.

Show other versions (1)

<h4>Aim</h4>The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cos...

Full description

Saved in:
Bibliographic Details
Main Authors: Bart Slob, Tanja Fens, Maaike Weersma, Maarten Postma, Cornelis Boersma, Lisa de Jong
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0315509
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items